BTK and hepatocellular carcinoma: Based on the above results that ATK depletion attenuated HCC cell resistance to Lenvatinib, we further employed a well-validated AKT inhibitor, AZD5363, to further confirm whether AKT inhibition contributes to overcome Lenvatinib resistance.